A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon

Journal of Virology

Volumn 74, Issue 21, 2000, Pages 10249-10255

  Goepfert, P A ^a   Bansal, A ^a   Edwards, B H ^a   Ritter G D , Jr ^a   Tellez, I ^a   McPherson, S A ^a   Sabbaj, S ^a   Mulligan, M J ^a  

^a BBRB 220 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HLA A2 ANTIGEN; TETRAMER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE; VIRUS DETECTION; VIRUS PATHOGENESIS;

BIOPOLYMERS; CHROMIUM; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HLA-A2 ANTIGEN; HUMAN; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033771293     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.21.10249-10255.2000     Document Type: Article

References (43)

1. Phenotypic analysis of antigen-specific T tymphocytes
2. Longitudinal study of HIV-specific cytotoxic lymphocytes in HIV type 1-infected patients: Relative balance between host immune response and the spread of HIV type 1 infection
3. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
4. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
5. + CTL responses in seronegative volunteers
6. Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
7. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
8. + T cells in HIV-infected progressors and long-term nonprogressors
9. High frequency of memory and effector gag-specific cytotoxic T lymphocytes in HIV-seropositive individuals
10. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA) - Identical siblings with HLA-A*0201 are influenced by epitope mutation
11. Anti-HIV cellular immunity: Recent advances toward vaccine design
12. + T cells in individuals receiving highly active antiretroviral therapy (HAART)
13. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle
14. + T cells
15. + T cell depletion in simian immunodeficiency virus-infected macaques
16. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells
17. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
18. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
19. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
20. + memory T cells
21. A recombinant vaccinia virus-based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
22. A critical role for conserved residues in the cleft of HLA-A2 in presentation of a nonapeptide to T cells
23. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
24. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC
25. A new look at T cells
26. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease
27. + T cells using an ELISPOT assay
28. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
29. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
30. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides
31. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
32. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
33. + T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
34. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS
35. + T cell responses associated with control of viremia
36. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide-specific T lymphocytes from peripheral blood
37. + lymphocytes
38. + T cells
39. + T cells specific for EBV in healthy virus carriers
40. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1
41. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein
42. Viral immune evasion due to persistence of activated T cells without effector function